Ajanta Pharma Sees Profit Growth with Robust Branded Generics Sales

Ajanta Pharma has announced a 4% rise in its consolidated profit after tax, reaching Rs 255 crore for the first quarter ending June 30, 2025. The climb is credited to robust sales of branded generics, as per the company's recent regulatory filing.

The Mumbai-based pharmaceutical company's revenue from operations surged to Rs 1,303 crore during this period, reflecting a marked increase from Rs 1,145 crore recorded in the year-ago quarter. Branded generics in India, Asia, and Africa rose by 9% year-on-year to Rs 941 crore in the current fiscal's April to June quarter.

Ajanta Pharma's US market emulated this positive trend with a substantial 36% year-on-year growth, bringing generics sales to Rs 310 crore compared to Rs 228 crore last year. Meanwhile, the company's shares closed nearly 1% down at Rs 2,753.65 on the BSE.